Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dupilumab reduces exacerbations independent of changes in biomarkers in moderate-to-severe asthma.
Pavord ID, Casale TB, Corren J, FitzGerald MJ, Deniz Y, Altincatal A, Gall R, Pandit-Abid N, Radwan A, Jacob-Nara JA, Rowe PJ, Busse WW. Pavord ID, et al. Among authors: pandit abid n. J Allergy Clin Immunol Pract. 2024 Mar 28:S2213-2198(24)00306-4. doi: 10.1016/j.jaip.2024.03.031. Online ahead of print. J Allergy Clin Immunol Pract. 2024. PMID: 38555079 Free article.
Biomarkers Associated with Lung Function Decline and Dupilumab Response in Patients with Asthma.
Pavord ID, De Prado Gómez L, Brusselle G, Jackson DJ, Brightling CE, Papi A, Maspero JF, Rabe KF, Korn S, Zhang M, Soler X, Jacob-Nara JA, Hardin M; QUEST Lung Function Decline Study Group. Pavord ID, et al. Am J Respir Crit Care Med. 2024 Apr 15;209(8):1031-1033. doi: 10.1164/rccm.202310-1751LE. Am J Respir Crit Care Med. 2024. PMID: 38329781 No abstract available.
Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma.
Papi A, Castro M, Corren J, Pavord ID, Tohda Y, Altincatal A, Pandit-Abid N, Laws E, Akinlade B, Mannent LP, Gall R, Jacob-Nara JA, Deniz Y, Rowe PJ, Lederer DJ, Hardin M. Papi A, et al. Among authors: pandit abid n. Respir Med. 2024 Apr;224:107535. doi: 10.1016/j.rmed.2024.107535. Epub 2024 Jan 23. Respir Med. 2024. PMID: 38272376 Free article.
Long-term efficacy of dupilumab in severe asthma by baseline oral corticosteroid dose.
Domingo C, Rabe KF, Price D, Brusselle G, Wechsler ME, Xia C, Pandit-Abid N, Gall R, Rowe PJ, Deniz Y, Jacob-Nara JA, Radwan A. Domingo C, et al. Among authors: pandit abid n. ERJ Open Res. 2023 Nov 13;9(6):00056-2023. doi: 10.1183/23120541.00056-2023. eCollection 2023 Nov. ERJ Open Res. 2023. PMID: 38020559 Free PMC article.
Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma.
Corren J, Katelaris CH, Castro M, Maspero JF, Humbert M, Halpin DMG, Altincatal A, Pandit-Abid N, Soler X, Radwan A, Jacob-Nara JA, Deniz Y, Rowe PJ. Corren J, et al. Among authors: pandit abid n. ERJ Open Res. 2023 Oct 16;9(5):00037-2023. doi: 10.1183/23120541.00037-2023. eCollection 2023 Sep. ERJ Open Res. 2023. PMID: 37859672 Free PMC article.
Clinical Efficacy among Patients with Chronic Rhinosinusitis with Nasal Polyps and Clinical Features of Obstructive Lung Disease: Post Hoc Analysis of the Phase III SINUS-24 and SINUS-52 Studies.
Maspero JF, Bachert C, Martinez FJ, Hanania NA, Ortiz B, Patel N, Mannent LP, Praestgaard A, Pandit-Abid N, Siddiqui S, Hardin M. Maspero JF, et al. Among authors: pandit abid n. J Asthma Allergy. 2023 Mar 31;16:333-342. doi: 10.2147/JAA.S357393. eCollection 2023. J Asthma Allergy. 2023. PMID: 37026112 Free PMC article.
18 results